1. Corporate Presentation J.B.Chemicals & Pharmaceuticals Ltd.

2. Forward Looking Statements
In this presentation we have disclosed forward looking information to enable investors to comprehend our prospects and take informed investment decisions.
This presentation and other statements, written and oral, that we periodically make contain forward looking statements that set out anticipated results based on the management’s plan and assumptions.
We have tried wherever possible to identify such statements by using words such as ‘anticipate’, ‘aims’ ‘estimate’, ‘expects’, ‘project’, ‘intends’, ‘plans’, ‘believes’, and words of similar substance in connection with any discussion of future performance. We cannot guarantee that these forward looking statements will be realized, although we believe we have been prudent in assumptions.
The achievement of results is subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Everybody should bear this in mind.

3. COMPANY
BUSINESS UNITS
MANUFACTURING
STRATEGY

4. Background
The name J. B. Chemicals & Pharmaceuticals Ltd. was christened after Mr. J. B. Mody who is the Chairman and founder of JBCPL
JBCPL is a leading and publicly traded pharmaceutical company in India
Leading by the vision and dynamism of Mr. J. B. Mody, a visionary and pioneer with an experience of over five decades in the pharmaceutical industry, the group has diversified into different sectors

5. Brief on JBCPL Incorporated in 1976 with an IPO in 1985
Listed on the BSE and NSE with a market cap of USD 110 million
Manufacturing facilities in Gujarat and Maharashtra for formulations and API
Subsidiary in South Africa and Russia
Total employee strength of 2900

6. 2012-13 Quarterly Revenues & Profits
Rs. in crores
Financial year: April 2012 – March 2013

7. 2012-13 Quarterly Revenues & Profits
USD in millions
Financial year: April 2012 – March 2013

8. Annual Revenues & Profits
Rs. in crores
* Divestment of Russia-CIS OTC business to J&J

9. Annual Revenues & Profits
USD in millions
* Divestment of Russia-CIS OTC business to J&J

10. Strategic Business Units
INDIA
Prescription and Hospital
CONTRAST MEDIA
GLOBAL
ANDA
Contract Manufacturing
Branded Generics
OTC
Contrast Media
API
RUSSIA & CIS
OTC, Prescription, Hospital
JBCPL
INDIA
40%
CONTRAST MEDIA 5%
GLOBAL
30%
API 7%
RUSSIA & CIS
18%
BUSINESS DEVELOPMENT

11. India Prescription products
Domestic market estimated at about USD 11 billion and growing by about 18% as per ORG
JBCPL Ranked 35th (ORG) with 3 brands featuring in top 300 brands reported by ORG
JBCPL continued consolidation process during , and adopted key brands focus marketing strategy
Top 4 therapeutic segments: Gastro-enterology, Cardiovascular, Pain management and Antibiotic
Acute segment contributes about 82% of total sales
Current field force: 1100 sales representatives

12. India
Growth Plan
JBCPL has placed increased concentration on domestic market for next level growth.
Increase in field force
New product introductions
JBCPL plans to increase field force to 1500 in This is aimed at strengthening rural market presence with strength increase in urban market too

13. Contrast Media – niche focus
Contrast Media Products
Caters to niche radio-diagnostic products used in CT Scan, MRI and Cath Lab through 30 sales representatives
Iopamidol
Iohexol
Gadopentetate dimeglumine
Diatrizoate Meglumine
In-licensed a new Ultrasound Contrast Imagining product (Definity) of Lantheus Medical Imaging Inc. from USA

14. Russia/Ukraine/CIS Latvia Estonia Lithuania Byelorussia Ukraine
Maldova
Russia
Georgia
Armenia
Kazakhstan
Azerbaijan
Turkmenistan
Uzbekistan
Mongolia
Kyrghyztan
Tajikistan

15. Russia/Ukraine/CIS
Russian market is estimated to be about US $12 billion at retail level, growing by about 7% in value annually
JBCPL is ranked amongst the top Indian companies
Entered Russia in 1992
Offices in Russia/Ukraine and some CIS countries

16. Russia/Ukraine/CIS
Divested OTC portfolio to Johnson & Johnson in May 2011
Contract manufacturing for J&J for these OTC products
Prescription business continues through wholly owned subsidiary in Russia

17. Global
Contract Manufacturing and Product pipeline will increase to fuel growth
Activity wise breakup

18. Global
Top markets breakup

19. South Africa
In 2007, JBCPL has made strategic investment in Biotech Laboratories (Pty) Ltd., South Africa, a BEE marketing and sales, marketing and distribution company
Have 49% equity stake with preference shares to take it to 51%
Robust products pipeline to strengthen direct business with Biotech

20. Contract Manufacturing
Contract Manufacturing (Clear Focus)
Projects awarded by multinationals globally
More than 10 clients
Tailor made services for customers
Injectables
Vials
Ampoules
Form Fill Sealed
Semi-solid
Creams
Ointments
Gels
Solid
Tablets
Lozenges
Herbal
Medicated

21. Contract Manufacturing
Complete package
New Product development
Analytics services
Technology transfer
Regulatory support
Manufacturing

22. Lozenges
Lozenges, a JBCPL niche strength, has excellent scope in global market
Medicated and Herbal
We manufacture lozenges under our own brands and private label
Private label lozenges for leading UK/EU, South African, Australian and Canadian companies.

23. API Business
JBCPL manufactures 2 APIs
one of the largest manufacturer of Diclofenac Sodium (BP, EP, USP) and Nifedipine

24. Brands | Assets Zecuf herbal Cough and Cold Nicardia (Nifedipine)
Anti-hypertensive
Metrogyl (Metronidazole)
Anaerobicide
Rantac (Ranitidine)
Anti-peptic ulcerant
Panum (Pantaprazole)
OF (Ofloxacin)
Antibiotic
Dicloran (Diclofenac Sodium)
NSAID

25. Manufacturing Facilities
At Daman
Located at Kadaiya, Daman
Manufactures lozenges and tablets
Lozenges approved by:
UK MHRA
TGA Australia
MCC South Africa
FDB Ghana

26. Manufacturing Facilities
At Gujarat
Plant TI – 10
Located at Panoli
Manufactures tablets
Facility approved by
US FDA
UK MHRA
TGA Australia
MCC South Africa
INVIMA Colombia
Germany (EU-GMP)

27. Manufacturing Facilities
At Gujarat
Plant IV -17
Located at Panoli
Manufactures injectables -
FFS, vials and ampoules
Facility approved by:
MCC South Africa
INVIMA Colombia

28. Manufacturing Facilities
At Gujarat
Plant IV -14
Located at Panoli
Manufactures injectables,
ointments & cold rubs
Facility approved by:
MCC South Africa
NDA Uganda
Pharmacy Board Tanzania
INVIMA Colombia

29. Manufacturing Facilities
At Gujarat
Plant L-6
Located at Panoli
Manufactures herbal liquids

30. Manufacturing Facilities
At Gujarat
Plant D 9
Located at Panoli
Manufactures Diclofenac API
Facility approved by:
US FDA
Germany EU-GMP

31. Manufacturing Facilities
At Gujarat
Plant UM 12
Located at Ankleshwar
Manufactures tablets and liquids
Facility approved by:
NDA - Uganda (Tablets & liquids)
Pharmacy Board - Tanzania (liquid)

32. Strategy ANDA: Develop and manufacture products for USA market
Contract Manufacturing: Increase our customer base by providing quality products at cost effective prices
Russia marketing: Form JV/Partnerships for marketing
New Territories: Expand into newer territories through partnerships
Capacities: Enhance capacities in for ANDA and contract manufacturing
tablets
Injectables
Lozenges

33. Thank You J.B.Chemicals & Pharmaceuticals Ltd.|
J.B.Chemicals & Pharmaceuticals Ltd.